Esperion Therapeutics (ESPR) Misses Q3 EPS by 18c
Tweet
Share
E-mail
Get Alerts ESPR Hot Sheet
Join SI Premium – FREE
Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.16), $0.18 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $87.3 million versus the consensus estimate of $92.5 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Paramount Skydance clears global regulators for WBD deal, faces state AG suit
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
